Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06696443 · ClinicalTrials.gov registry record · Phase 3
Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)
A Phase 3 study of Diabetic Peripheral Neuropathic Pain, sponsored by Vertex Pharmaceuticals Incorporated.
- Active
- Registry status
- Phase 3
- Development phase
- 455
- Enrollment target
- 20
- Study locations
NCT06696443: Active Phase 3 study of Diabetic Peripheral Neuropathic Pain, sponsored by Vertex Pharmaceuticals Incorporated.
NCT06696443 is a Phase 3 study of Diabetic Peripheral Neuropathic Pain that is active but no longer recruiting, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 455 participants, above the 372-participant average among 7 other Diabetic Peripheral Neuropathic Pain trials with a reported enrollment target (22% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06696443, a Phase 3 study of Diabetic Peripheral Neuropathic Pain, is active but no longer recruiting, sponsored by Vertex Pharmaceuticals Incorporated.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 455 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the long-term safety and tolerability of SUZ and long-term effectiveness of SUZ in treating pain associated with DPN.
Conditions Studied
Interventions
- DRUG Suzetrigine
Study Locations (20)
Florida
- AMR-Miami - Coral Gables
- Accel Research - Deland - DeLand
- Suncoast Research Associates - Miami - Doral
- AMR Fort Myers (The Clinical Study Center) - Fort Myers
- Velocity Clinical Research - Hallandale Beach - Hallandale
- CNS Healthcare - Jacksonville - Jacksonville
- Accel Research Site - St. Petersburg/Largo - Largo
- Accel Research Sites - Maitland - Maitland
California
- Neuro-Pain Medical Center - Fresno
- Long Beach Research Institute - Long Beach
- Angel City Research, Inc - Los Angeles
- Empire Clinical Research - Pomona
- Clinical Trials Research - Sacramento
- Velocity Clinical Research, San Bernardino - San Bernardino
- SCLA Management - Pain Management and Injury Relief - Thousand Oaks
Alabama
- Pinnacle Research Group, LLC - Anniston
- AMR Daphne, AL - Daphne
Arizona
- Scottsdale Clinical Trials - Scottsdale
Colorado
- Velocity Clinical Research - Denver - Englewood
District of Columbia
- Velocity Clinical Research - Washington DC - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 455 participants |
| Start Date | 2024-12-18 |
| Est. Completion | 2027-01-25 |
| Phase | Phase 3 |
What the registry record for NCT06696443 still lists
NCT06696443 is an interventional study that assigns participants to a tested intervention. The registered 455 participants enrollment target is mid-sized for trials with a published cap, above the 372-participant average among 7 other Diabetic Peripheral Neuropathic Pain trials with a reported enrollment target (22% higher).
The record links to 1 condition, with Diabetic Peripheral Neuropathic Pain appearing as the primary indexed condition, and to 1 intervention - of which Suzetrigine is the first listed.
NCT06696443 names 20 study sites across 6 states, led by Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT06696443 about?
NCT06696443 is a clinical study titled "Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)". The purpose of this study is to evaluate the long-term safety and tolerability of SUZ and long-term effectiveness of SUZ in treating pain associated with DPN.
What is the current status of trial NCT06696443?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 455 participants. The study started on 2024-12-18. Estimated completion is 2027-01-25.
What conditions does trial NCT06696443 study?
This clinical trial studies the following conditions: Diabetic Peripheral Neuropathic Pain.
What interventions are being tested in trial NCT06696443?
The interventions under investigation include: Suzetrigine (DRUG).
Who is sponsoring clinical trial NCT06696443?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06696443 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Peripheral Neuropathic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
RECRUITING · Phase 3
-
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
RECRUITING · Phase 3
-
MAD Study to Assess the Safety, Tolerability, PKs and Efficacy of YJ001 for Spray Use in Patients With DPNP
RECRUITING · Phase 1
-
Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
RECRUITING · Phase 2
-
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain
RECRUITING · Phase 2
-
A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05541016 · 455 participants · Phase 2
De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA
- NCT06079346 · 455 participants · Phase 2
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
- NCT06504446 · 455 participants · Phase 2
Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough
- NCT06725030 · 455 participants
A Post-market, Real-world Experience: Expanding Access to Care by Incorporating the Symani® Surgical System and Enabling Surgeons
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI